Top Oncology Pipelines to Watch in 2026
The candidates that will reshape onco economics.
A defensible view of the most consequential oncology pipelines to track in 2026 — by indication, modality, sponsor and PoS-weighted impact.
"Which 2026 oncology assets will materially shift TA economics — and which are noise?"
ADCs, bispecifics, IO combinations, KRAS inhibitors and cell-therapy iterations dominate the consequential 2026 oncology pipeline. Most public lists overstate; PoS-weighted lists compress sharply.
The 2026 oncology pipeline is the most crowded and most economically consequential in pharma history. The teams that win the next cycle separate signal from noise on three axes: modality, sponsor, and combination context.
Five modality clusters define the cycle
ADCs, bispecifics, KRAS inhibitors, IO combinations and next-gen cell therapy. Most consequential 2026–28 launches sit in these five clusters. Map your TA exposure cluster-by-cluster.
What we’re seeing in the data.
ADCs continue platform expansion
Beyond HER2 — TROP2, B7-H3 and Nectin-4 ADCs are scaling.
Bispecifics broaden in B-cell
CD20×CD3 and similar bispecifics are deepening the B-cell market.
KRAS inhibitors mature
G12C and G12D inhibitor combinations expand the addressable cohort.
IO combinations consolidate
PD-1 + LAG3, TIGIT and bispecifics define next-gen IO.
How to think about it.
-
01
Cluster by modality
ADC, bispecific, KRAS, IO+, cell.
-
02
Filter by indication
TA × biomarker × line of therapy.
-
03
Score sponsor & data
Late-stage data quality + sponsor track record.
-
04
Apply PoS & timeline
Realistic launches by 2027–28.
-
05
Forecast peak share
TAM × clinical superiority × access readiness.
What separates a good answer from a defensible one.
Multiple combinations targeting same line cap individual share.
ADC and ATMP scale-up is a real constraint.
Premium pricing facing growing payer pressure.
Companion diagnostics define addressable cohort.
Where the signal comes from.
Common questions.
Why do most "top pipeline" lists overstate?
They count assets not PoS-weight launches. Apply attrition, timeline and reimbursement realism.
Which onco modality is most disruptive?
ADCs in 2026–27; in-vivo cell therapy by 2028–30.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist